Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | TGM2 | P21980 | 2/20 | 0.42 |
| ▸ | PPOX | P50336 | 1/20 | 0.39 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6279427 | 0.87 | CHEK1 (0.50) | CHEK1CES1TGM2PPOXIDO1 | |
| SCHEMBL6827492 | 0.82 | CHEK1 (0.53) | CHEK1CES1TGM2IDO1TDO2 | |
| SCHEMBL4856929 | 0.80 | CHEK1 (0.50) | CHEK1CES1MDM2KDR | |
| SCHEMBL4858965 | 0.78 | CHEK1 (0.60) | CHEK1CES1TGM2PPOXCSNK1G1 | |
| SCHEMBL4848111 | 0.76 | CHEK1 (0.58) | CHEK1CES1TGM2PPOXCSNK1G1 | |
| SCHEMBL2705692 | 0.76 | CSNK1G1 (0.49) | CHEK1CSNK1G1EGFRERBB2PDGFRB | |
| SCHEMBL4853307 | 0.76 | CHEK1 (0.65) | CHEK1CES1TGM2PPOXCSNK1G1 | |
| SCHEMBL4856162 | 0.76 | CHEK1 (0.65) | CHEK1CES1TGM2PPOXCSNK1G1 | |
| SCHEMBL4858805 | 0.75 | CHEK1 (0.58) | CHEK1CES1TGM2PPOXCSNK1G1 | |
| SCHEMBL4855620 | 0.75 | CHEK1 (0.58) | CHEK1CES1TGM2PPOXCSNK1G1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885CES1 2761/4885TGM2 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.